Approximately half of patients diagnosed with cancer are ⩾70 years, and owing to an aging population the number of older cancer patients is rapidly increasing ([@bib33]; [@bib5]). The heterogenic health status of this large cohort of patients complicates treatment decisions. Age-related decrease in physiological reserves and co-existing problems, such as physical and cognitive impairments and comorbidities that may affect both treatment and outcomes ([@bib7]; [@bib19]), vary considerably between individuals. For appropriate treatment planning it is paramount to identify those who are fit and may tolerate standard treatment, and those who are frail and may profit from less-intensive treatment ([@bib2]).

Frailty is widely recognised as a syndrome of increased vulnerability to adverse changes in health status ([@bib6]). There is, however, no consensus on how to best identify frail patients. In clinical trials, the Fried Phenotype model or indices based on accumulation of deficits ([@bib15]) are commonly used. Geriatric assessment (GA) includes a systematic assessment of areas where problems are frequent in older age, such as comorbidity, medication, physical and cognitive function, and is the most frequently applied approach to assess vulnerability and frailty in cancer patients ([@bib13]). Consensus statements on what GA in this setting should include are, however, not entirely consistent ([@bib36]; [@bib22]) and there are no agreed criteria to define frailty based on GA. Thus, varying domains and thresholds have been used ([@bib13]), and several studies have applied frailty criteria as proposed by [@bib2], or a modification of these ([@bib3]; [@bib34]; [@bib19]). Frailty defined according to this approach is demonstrated to be prognostic for survival ([@bib3]; [@bib34]; [@bib25]). Performing a full GA is time and resource consuming, and although highly recommended, is yet to be established in routine clinical practice ([@bib21]). Easily applicable screening tools have therefore been sought, and some have documented ability to predict survival ([@bib32]). However, compared with a complete GA, none has demonstrated sufficient sensitivity and specificity to reliably identify frail patients ([@bib12]). Based on the excellent prognostic performance of simple physician-rated scales such as the Eastern Cooperative Oncology Group Performance Status (PS) ([@bib31]), few studies have investigated whether physicians' clinical judgement is an equally effective screening tool for frailty ([@bib35]; [@bib34]; [@bib7]). The results suggest that physicians are more conservative and rate fewer patients as unfit or potentially vulnerable than those identified by GA ([@bib35]; [@bib34]; [@bib7]). However, two of these studies either used a retrospective evaluation of the patients' overall health at the time of diagnosis ([@bib7]) or the physicians' decision for palliative or more intensive treatment for comparison with GA ([@bib34]). Only one study actually asked the physician to identify frailty, and no treatment outcomes were reported ([@bib35]). To establish the ability of physicians' frailty ratings to predict outcomes, i.e., in comparison with GA, prospective comparative studies are needed.

In the present study we aimed to (1) compare oncologists' classification of frailty with a systematic modified geriatric assessment (mGA) of frailty, (2) describe what information oncologists emphasise when rating frailty and (3) investigate the associations of these frailty classifications with overall survival (OS).

Materials and methods
=====================

Patients
--------

From January 2013 until April 2015, patients referred for medical cancer treatment were consecutively recruited at eight different outpatient oncology clinics in South East Norway (two university hospitals and six local hospitals). Eligible patients were ⩾70 years with a histologically confirmed solid tumour (newly diagnosed or first relapse after previous curative treatment). All patients provided written, informed consent. The patients were identified by referral, and oncology nurses with specific training in study procedures performed baseline interviews and mGA-testing, aiming at retrieving all information before treatment started.

Baseline assessments
--------------------

Medical data were reported by the oncologists and included cancer type (ICD-10), stage of disease (local, locally advanced or metastatic), location of metastatic sites, planned treatment and rating of PS.

We defined our GA as a modified GA (mGA) as it was not performed by a geriatrician or a geriatric team. The mGA included assessment of eight domains. Nutritional status and related symptoms were registered partly by nurses and partly by patients' self-report. Medication, falls, physical and cognitive function were tested and/or registered by the oncology nurses. Comorbidity, activities of daily living (ADL) and depressive symptoms were assessed by patients' self-report.

Nutritional status was assessed using the Patient-Generated Subjective Global Assessment (PG-SGA) ([@bib26]; [@bib28]). The PG-SGA includes two parts. One is a patient questionnaire about weight loss and nutritional symptoms, whereas the other is filled in by health professionals and includes a categorisation of a patient's overall nutritional status into (A) well-nourished, (B) moderately malnourished/suspected malnutrition and (C) severely malnourished. Severely malnourished patients are defined as having severe weight loss, visible loss of subcutaneous fat tissue and muscle mass, with or without the presence of oedema. Comorbidity was registered using the Physical Health Section, a subscale of the Older Americans' Resources and Services Questionnaire (OARS) ([@bib9]; [@bib16]). The Physical Health Section consists of a list of 15 diseases/conditions as well as a grading of how these conditions affect daily activities. Medication was registered according to the Anatomical Therapeutic Chemical Classification System. Falls were defined as unintentional events resulting in a laying position on the floor, the ground or other lower level, and the number of falls the last 6 months was registered. To screen for deficits in basic ADL we used question 5 ('Do you need help with eating, dressing, washing yourself or using the toilet?') from the 'European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ C30)([@bib1]). Questions 1--28 in EORTC QLQ C30 are graded into four categories, 'Not at all', 'A little', 'Quite a bit' and 'Very much'. Depressive symptoms were self-reported on the geriatric depression scale (GDS-15) ([@bib39]). This scale consists of 15 items and the total score ranges from 0 to 15. A higher score indicates more depressive symptoms. Physical performance was tested using the Timed Up and Go test (TUG) ([@bib29]) which registers the time it takes to rise from an arm chair, walk three metres, turn, walk back and sit down, and patients were instructed to walk at a fast pace ([@bib4]). Cognitive function was assessed using the Norwegian Revised Mini Mental State Examination (MMSE-NR) ([@bib10]). MMSE-NR consists of 20 items and the total score ranges from 0 to 30. The higher score, the better the cognitive function.

The oncologists were asked to classify the patient as fit, intermediate or frail after their first consultation at baseline. Prior to this, they were blinded for the results from the mGA and not given any specific instructions or training. In case the mGA assessments revealed severe medical problems requiring attention, the nurses gave this information to the patients' oncologist afterwards.

Information regarding administered cancer treatment and date of death was registered from the patients' medical records. OS was defined as the main outcome. The study was not designed to assess cancer-specific survival.

Statistical analyses
--------------------

To define frailty according to mGA, we used criteria similar to the modified Balducci criteria formerly applied by [@bib19] and [@bib25], and defined patients as frail if they met one of the following criteria: dependencies in ADL, had significant comorbidity, or one or more geriatric syndromes defined as impaired function according to MMSE (cognitive function), GDS (depression), SGA (malnutrition) or frequency of falls. Furthermore, in accordance with Winograd's criteria for frailty ([@bib38]) and similar to Kristjansson *et al* ([@bib19]), we included polypharmacy as a criterion, but also added impairment according to TUG, which has been reported as a sensitive and specific measure of frailty ([@bib30]). Pre-defined cutoffs for impaired function within each domain are summarised in [Table 1](#tbl1){ref-type="table"}. To enable comparisons between the two procedures for assessment of frailty, and because very few patients were considered frail by the oncologists, their original threefold classification was dichotomised to either onc-non-frail (patients considered fit) or onc-frail (patients considered frail or intermediate).

Demographic and clinical characteristics as well as mGA domains at baseline were presented as median (min, max), mean (standard deviation (SD)), or frequencies and percentages.

Medical and sociodemographic factors were compared between groups by independent sample *t*-tests or *χ*^2^-test. The agreement between mGA-non-frail/mGA-frail and the onc-non-frail/onc-frail was assessed by kappa statistics.

Survival time was defined as time from inclusion until death or the last observation date. PS was dichotomised as 0--1 and 2--4. Treatment was classified into four categories based on the first treatment the patients received; (1) Curative treatment, i.e., patients referred for neoadjuvant treatment, adjuvant treatment after curative surgery or curative radiotherapy (2) Palliative chemotherapy, (3) Other palliative systemic cancer treatment (4) Non-systemic palliative treatment the first two months after inclusion (i.e., radiotherapy, palliative surgery or palliative care). The association between mGA-frailty and OS was first assessed by bivariate Cox regression model. The multiple Cox regression model was estimated to adjust for age, sex, cancer type, PS, stage and treatment. The association between clinicians' judgement of being onc-frail and OS was analysed accordingly. Proportional hazards assumption was assessed by examining Schoenfeld's residuals. Multicollinearity issue was considered by calculating variance inflation factor. Kaplan--Meier OS curves were presented. Significance level was set at 0.05.

Missing values in MMSE (*n*=3) and GDS-15 (*n*=27) were imputed by drawing one random number per value from the empirical distribution based on non-missing values. In total, 31 patients had one or several missing items in the OARS subscale. Missing items on the OARS subscale were imputed by retrieving information from hospital charts.

The study was approved by the Regional Committee for Medical and Health Research Ethics South East Norway and was registered at clinicaltrials.gov (NCT01742442).

Results
=======

Study recruitment and patient characteristics
---------------------------------------------

The approximate time needed to perform the interview and testing by study nurses was 45 min. A total of 307 patients were enroled, 18 had missing baseline questionnaires and one withdrew consent. Thus, 288 (94%) patients underwent the mGA and 286 (93%) were assessed by oncologists. All patients were followed until death or last observation date. The median follow-up time was 16.9 months (min 0.6, max 40). Last observation date was 31 May 2016. By then, 158 (55%) patients had died.

Baseline characteristics are shown in [Table 2](#tbl2){ref-type="table"}. Median age was 77 years (min 70, max 95), 126 (44%) were females. The most common cancer types were colorectal (*n*=83, 29%), lung (*n*=59, 21%) and prostate cancer (*n*=56, 19%), the majority of patients had PS 0--1 (*n*=244, 85%) and received palliative treatment (*n*=197, 68%). Chemotherapy was the primary systemic treatment for 200 (69%) patients, (palliative *n*=126, adjuvant *n*=74). Almost all patients lived at home (*n*=275, 96%), and 93 (34%) of the patients living at home lived alone.

Frailty according to classification procedure
---------------------------------------------

According to mGA, 140 (49%) patients were frail. The three most common frailty domains were comorbidity (*n*=82, 28%), polypharmacy (*n*=37, 13%) and malnutrition (*n*=43, 15%) ([Table 3](#tbl3){ref-type="table"}). Overall, 73 (25%) patients had a deficit in one mGA domain, 42 (15%) in two domains and 25 (9%) in three or more. The oncologists considered 15 patients (5%) as frail and 89 (31%) as intermediate, giving a total of 104 (36%) onc-frail according to the dichotomised classification.

According to both classifications, there were significantly more patients with good PS and curative treatment among the non-frail than among the frail ([Table 2](#tbl2){ref-type="table"}). For the oncologists' classification, there were significant differences in cancer type and stage of disease between frail and non-frail patients, i.e., the most frequent cancer types were lung cancer in the onc-frail group and colorectal cancer in the onc-non-frail group. The onc-non-frail group also comprised significantly more patients with localised disease ([Table 2](#tbl2){ref-type="table"}). When comparing the mGA-frail and mGA-non-frail patients, similar findings with significantly more frequent lung cancer in the mGA-frail group was found for cancer type.

In the small subgroup classified as frail by the oncologists in the original threefold classification, all patients had a poor PS. All but one had PS 2--4, and of the six patients in the overall cohort with PS 3--4, five belonged to this group. Otherwise their characteristics were similar to the overall onc-frail cohort: The most common diagnosis was lung cancer (33%), the majority had metastatic disease (67%), and none received treatment with curative intention.

The mGA-frail/mGA-non-frail classification coincided with the onc-frail/onc-non-frail classification for 187 (65%) patients; 72 (25%) patients were found mGA-frail and onc-frail, while 115 (40%) patients were mGA-non-frail and onc-non-frail. A total of 67 (23%) patients were classified as mGA-frail, but judged by the clinicians to be fit. In comparison to those who were both mGA-frail and onc-frail, this group included fewer patients with lung cancer (15% *vs* 35%), and PS 2--4 (0% *vs* 44%), but larger proportions of patients with colorectal cancer (39% *vs* 17%), localised disease (30% *vs* 14%), PS 0 (61% *vs* 3%) and curative treatment (33% *vs* 13%) ([Supplementary material](#sup1){ref-type="supplementary-material"}). Hence, favourable cancer-related prognostic factors were more frequent among these 67 patients. In terms of mGA deficits, the majority of these patients had one deficit (*n*=46, 69%), whereas only 36% (*n*=26) had one deficit among those who were both mGA-frail and onc-frail. The most frequent mGA deficit missed by the oncologists was comorbidity. A total of 32 (11%) patients were mGA-non-frail and onc-frail. The frequency of established, negative cancer-related prognostic factors (lung cancer, poor PS, advanced stages of disease, palliative treatment) was high in this group, similar to the group that was both mGA-frail and onc-frail.

The kappa statistic was 0.30 (95% CI 0.19; 0.41), indicating only fair agreement between the oncologists' clinical judgement and the mGA.

OS according to frailty status
------------------------------

Median OS was 21.5 months, 93 (32%) patients died within their first year of follow-up. Both mGA-frail and onc-frail patients had poorer median OS compared with mGA-non-frail and onc-non-frail patients, respectively (mGA-frail: 15.0 months, mGA-non-frail: 29.1 months; *P*\<0.001) (onc-frail: 12.9 months, onc-non-frail: 27.4 months; *P*\<0.001). The few patients (5%) originally categorised as frail by the oncologists, had a median OS of only 7.4 months.

In bivariate Cox regression analyses, mGA-frail and onc-frail were both significantly negatively associated with OS ([Table 4](#tbl4){ref-type="table"} and [Figure 1A and B](#fig1){ref-type="fig"}). The HR for mGA-frail was 1.86 (95% CI 1.36; 2.56) (*P*\<0.001) and the HR for onc-frail was 1.94 (95% CI 1.41; 2.66) (*P*\<0.001). In analyses adjusting for age, sex, cancer type, PS, stage and treatment, only mGA frailty was an independent negative prognostic factor for OS with a HR of 1.61 (95% CI 1.14; 2.27) (*P*=0.007).

Finally, we explored possible differences in survival between four groups of patients; frail according to both assessments, non-frail according to both assessments, frail according to only the mGA, and frail only according to our onc-frail definition. Kaplan--Meier OS curves of these four patient groups are presented in [Figure 1C](#fig1){ref-type="fig"}. The group classified as non-frail according to both assessments had the best OS and the group classified as frail according to both assessments had the poorest OS.

Discussion
==========

We found only fair agreement between frailty classified by a systematic, modified GA, and the oncologists' clinical judgement of frailty. The oncologists classified very few patients as frail, and even when pooling frail and intermediate patients (according to the oncologists), they missed almost half of the patients who were frail according to the mGA. The oncologists most commonly missed frailty due to comorbidity. Although both classification procedures succeeded in identifying patients with poorer survival, only mGA-frailty remained significantly associated to OS when other, established cancer related prognostic factors such as cancer type, stage, PS and treatment were taken into account.

The finding that physicians are more conservative in rating frailty than a systematic GA is in accordance with the results of others ([@bib35]; [@bib34]). To the best of our knowledge, no former study of cancer patients has reported the prognostic value of frailty rated merely by the oncologists' clinical judgement. Consistent with our findings, a study found physician-rated health to be prognostic for survival ([@bib7]). In that study, however, being considered moderately ill/severely ill by the physician was an independent prognostic factor. As only breast cancer patients with stage I-III were included, and neither PS nor treatment was taken into account, differences in patient populations and analyses may explain why the results were somewhat different from ours. The prognostic importance of being mGA frail is consistent with previous studies ([@bib3]; [@bib34]; [@bib25]).

Our results suggest that the oncologists emphasise cancer-related factors when asked to rate frailty. Unfavourable prognostic factors such as lung cancer and advanced stage of disease were significantly more frequent in the onc-frail group compared with the onc-non-frail. The prognostic value of the oncologists' frailty assessment was not independent of other well-established prognostic factors. Furthermore, established negative cancer related prognostic factors were frequent among patients who were classified as onc-frail and not mGA frail, whereas the opposite was the case for those who were mGA-frail and onc-non-frail. Thus, the focus of the two classification procedures seemed to be different. Consequently, as demonstrated by our exploratory survival curves, the oncologists identified some patients with no mGA deficits and poor prognosis, whereas a larger group of patients who were frail according to mGA, and also had poorer prognosis compared to non-frail patients, was missed. This indicates that whereas the oncologists are experienced in evaluating cancer related health, training in identifying patients' overall vulnerability, including geriatric problems that may affect prognosis, is insufficient. Thus, increased education and awareness, and preferably inclusion of GA into routine clinical practice, may improve the physicians' ability to identify patients with otherwise unrecognised vulnerability ([@bib36]), prevent undertreatment and harmful overtreatment, and reduce the frequency and severity of treatment-related adverse events. However, prospective studies are needed to investigate if GA followed by targeted interventions can improve cancer patients' prognosis and outcomes of therapy.

Strengths of this study are inclusion at multiple centres, a heterogeneous patient group with respect to type of cancer, stage of disease and planned treatment thus representative of a large group of patients commonly seen in clinical practice. The cohort is also fairly large compared with other studies investigating frailty in older cancer patients ([@bib13]). Our mGA included the main domains recommended for GA ([@bib36]; [@bib22]), and we used well-known and validated scales ([@bib10]; [@bib9]; [@bib39]; [@bib29]; [@bib26]; [@bib28]). As patients needed to have deficits according to only one pre-defined criterion to be considered mGA-frail, we defined rather strict cutoff values in each of the domains included ([Table 1](#tbl1){ref-type="table"}) ([@bib2]; [@bib24]; [@bib11]; [@bib8]; [@bib27]; [@bib18]; [@bib25]; [@bib17]; [@bib37]). Still, the validity of our mGA and chosen cutoff is open for discussion as no gold standard currently exists ([@bib13]). More importantly, our definition of frailty may be questioned. It was, however, adapted from Balducci's criteria, and a similar approach has formerly been used and found superior to the physical phenotype of frailty in predicting post-operative complications in cancer patients, as well as being prognostic for survival ([@bib20]). We consider the inclusion of TUG as a frailty criterion is a potential strength rather than a weakness. Thus, the main objection may be the use of OARS for comorbidity registration, and that the severity of these conditions was not taken into account. Despite this, and although our comorbidity criterion was the most frequent reason for mGA frailty, we clearly demonstrate the independent prognostic value of our frailty measure. A frailty prevalence of 49% seems to be well within range of what has been observed in other studies ([@bib13]). Whether our definition actually capture the concept of frailty can, however, not be confirmed and the results should be interpreted with this in mind.

Another study limitation is the lack of data on eligible patients who were referred to the participating clinics and not included in our study. Furthermore, no information about the oncologists was systematically registered. Retrospectively, the participating clinics indicate that approximately 40 consultants evaluated from one to about 27--28 patients each, whereas 28 consultants are confirmed having assessed from one to seven of the mGA frail patients who were missed. An equal share of juniors and seniors with up to 30 years of oncology practice were represented. Thus, their oncological experience varied largely. This might, however, not be relevant when rating frailty. Insufficient training in assessing and managing geriatric syndromes is a widely recognised problem within several settings, including oncology ([@bib14]; [@bib23]), and our prevalence of physician-rated frailty was similar to a study in which participating physicians had at least 10 years of clinical experience ([@bib35]). It should also be noted that dichotomising the oncologists' original threefold classification and thereby comparing a group identified as either intermediate or frail with mGA frail patients, may introduce a risk of misinterpreting the oncologists' assessments. Based on the difference in median survival between the frail patients and the overall cohort defined as onc-frail, there is no doubt that the oncologists were able to identify groups of patients with poor and very poor prognosis, respectively. However, for both groups, this prognostication seemed to be based on well-known negative cancer-related factors. Hence, the fact remains that the oncologists missed to identify a considerable number of patients with poor prognosis and frailty due to geriatric deficits.

In conclusion, our results demonstrate that a mGA can aid the oncologists in identifying otherwise unrecognised frail older patients' with poor prognosis, as well as those non-frail patients without geriatric deficits and thus a better prognosis. The oncologists using their clinical judgement are good at evaluating cancer related prognostic factors, but may need training in geriatric assessment to better assess patient's overall vulnerability and prognosis. A geriatric assessment may thus provide information contributing to oncologists making more appropriate treatment decisions for their old cancer patients.

This study was funded by Innlandet Hospital Trust and registered at clinicaltrials.gov (NCT01742442). We want to thank the cancer clinics at Innlandet Hospital Trust, Oslo University Hospital and Akershus University Hospital for their participation in the study. A special thanks to the study nurses at all locations who participated in the inclusion and assessment of patients.
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###### 

Click here for additional data file.

![Kaplan Meier curves of overall survival (months) according to (**A**) mGA-non-frail/mGA frail, (**B**) onc-non-frail/onc-frail (**C**) both frailty classifications combined.](bjc2017202f1){#fig1}

###### The modified geriatric assessment[a](#t1-fn1){ref-type="fn"}

  **Domain**                                     **Scale**                                        **Range**                       **Rated by**                                                            **Cutoff value for frailty**                                                                                                    **Rationale for cutoff values**
  ---------------------------- --------------------------------------------- --------------------------------------------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Activities of daily living    EORTC QLQ-C30 Q5[b](#t1-fn2){ref-type="fn"}                                                          Patient      If reported yes a little/quite a bit/very much on the question 'Do you need help with eating, dressing, washing yourself or using the toilet'              ADL-deficiencies previously used in frailty classifications of cancer patients ([@bib2])
  Comorbidity                         OARS[c](#t1-fn3){ref-type="fn"}         0--15 (Higher score indicates more comorbidities)      Patient                                                                       \>3 points                                                                                     Threshold for shorter survival in previous study of cancer patients ([@bib18])
  Medications, polypharmacy           ATC[d](#t1-fn4){ref-type="fn"}                                0--13                           Nurse/ MD                                            \>7 regular medications (ointments & common vitamins excluded)                                                              Previously used in frailty classifications of cancer patients ([@bib25])
  Physical function                   TUG[e](#t1-fn5){ref-type="fn"}                                                                  Nurse                                                                       \>14 seconds                                                                      Similar cut-offs (⩾14/\>14.5) used to identify GA deficits in cancer trials ([@bib27]; [@bib17]; [@bib37])
  Cognitive function                  MMSE[f](#t1-fn6){ref-type="fn"}          0--30 (Higher score indicates better function)         Nurse                                                                        \<24 points                                                                                       Previously used in frailty classifications of cancer patients ([@bib25])
  Depressive symptoms                GDS-15[g](#t1-fn7){ref-type="fn"}          0--15 (Higher score indicates more symptoms)         Patient                                                                        ⩾7 points                                                                                                  Chosen to ensure high specificity ([@bib11]; [@bib8])
  Nutritional status                 PG-SGA[h](#t1-fn8){ref-type="fn"}                                                            Nurse/Patient                          Considered severely malnourished by nurse or self-reported weight loss ⩾10% the last 6 months.                           Weight loss ⩾ 10% the last six months is generally considered as an indicator of severe malnutrition ([@bib24])
  Falls                                                                                                                               Nurse                                                        Patient reports ⩾2 falls the last 6 months                                                                      Previously used to identify GA deficits in cancer trials ([@bib27]; [@bib17])

Patients were classified as mGA-frail if having ⩾ 1 of the criteria listed in the table.

The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire.

The Physical Health Section of the Older Americans' Resources and Services Questionnaire.

Anatomical Therapeutic Chemical Classification System.

Timed up and Go test.

Norwegian Revised Mini Mental State Examination.

Geriatric depression scale.

Patient-generated Subjective Global Assessment.

###### Baseline patient characteristics according to the mGA and the oncologists' classification

                                                                                     **Modified geriatric assessment**  **The oncologists classification**                                                                                                   
  --------------------------------------------------------------- ------------ ---- ----------------------------------- ------------------------------------ ------------ ---- ---------------------------------------- ------------ ---- ------------ ----- ----------------------------------------
  Age, mean (s.d.)                                                 76.9 (5.1)                   77.5 (5.2)                                                    76.2 (5.0)       **0.032**[a](#t2-fn1){ref-type="fn"}      77.2 (5.4)        76.6 (5.0)        0.346[a](#t2-fn1){ref-type="fn"}
  Gender                                                                                                                                                                                                                                                      
   Female                                                             126       44                  64                  46                                        62      42   0.513[b](#t2-fn2){ref-type="fn"}              43      41        81      45    0.604[b](#t2-fn2){ref-type="fn"}
  Cancer type                                                                                                                                                                                                                                                 
   Colorectal                                                          83       29                  39                  28                                        44      30                                                 18      17        64      35     
   Lung                                                                59       21                  35                  25                                        24      16                                                 34      33        25      14     
   Prostate                                                            56       19                  22                  16                                        34      23   **0.045**[b](#t2-fn2){ref-type="fn"}          25      24        31      17    **\<0.001**[b](#t2-fn2){ref-type="fn"}
   Other gastrointestinal                                              34       12                  19                  14                                        15      10                                                 8       8         25      14     
   Breast                                                              30       10                   9                  6                                         21      14                                                 6       6         24      13     
   Other                                                               26       9                   16                  11                                        10      7                                                  13      13        13      7      
  Stage                                                                                                                                                                                                                                                       
   Localised                                                           73       25                  30                  21                                        43      29                                                 12      12        61      34     
   Locally advanced                                                    55       19                  23                  16                                        32      22   0.091[b](#t2-fn2){ref-type="fn"}              22      21        32      18    **\<0.001**[b](#t2-fn2){ref-type="fn"}
   Distant metastasis                                                 160       56                  87                  62                                        73      49                                                 70      67        89      49     
  ECOG PS                                                                                                                                                                                                                                                     
   0--1                                                               244       85                  106                 76                                       138      93                                                 62      60       181      100    
   2--4                                                                43       15                  33                  24                                        10      7    **\<0.001**[b](#t2-fn2){ref-type="fn"}        42      40        0             **\<0.001**[b](#t2-fn2){ref-type="fn"}
   Missing                                                             1                             1                                                                                                                       0                 1              
  Treatment                                                                                                                                                                                                                                                   
   Curative[c](#t2-fn3){ref-type="fn"}                                 91       32                  31                  22                                        60      41                                                 14      14        77      42     
   Palliative chemotherapy                                            126       44                  75                  54                                        51      35                                                 60      58        66      36     
   Other palliative systemic cancer treatment                          51       18                  22                  16                                        29      20   **0.002**[b](#t2-fn2){ref-type="fn"}          21      20        30      17    **\<0.001**[b](#t2-fn2){ref-type="fn"}
   Non-systemic palliative treatment[d](#t2-fn4){ref-type="fn"}        20       7                   12                  9                                         8       5                                                  9       9         9       5      

Independent samples t-test.

Pearson *χ*^2^-test.

Referred for neoadjuvant treatment, adjuvant treatment after curative surgery or curative radiotherapy.

Radiotherapy, palliative surgery or palliative care.

Bold numbers are statistically significant.

###### Frailty according to mGA category and median scores of the different scales

                                                                **No. frail**   **%**   **Median (min, max)**   **No. missing**
  ------------------------------------------------------------- --------------- ------- ----------------------- -----------------
  Nutritional status, malnutrition[a](#t3-fn1){ref-type="fn"}   43              15                              24
  Comorbidity (OARS\>3)                                         82              28      3 (0--9)                1
  Medications, polypharmacy (\>7)                               37              13      4 (0--13)               0
  Falls (⩾2)                                                    10              3                               1
  Activities of daily living[b](#t3-fn2){ref-type="fn"}         12              4                               5
  Depressive symptoms (GDS⩾7)                                   35              12      2 (0--13)               4
  Physical function (TUG\>14s)                                  18              6       8 (4--25)               13
  Cognitive function (MMSE\<24)                                 9               3       29 (19--30)             0
  Frail according to any category                               140             49                               

Self-reported ⩾ 10% weight loss the last 6 months or classified as severely malnourished by nurse. No. with missing information about weight loss last 6 months from patient.

Patient-reported on Question 5 EORTC QLQ C30.

###### Cox regression analyses of the association between both frailty classifications and overall survival

                                                **Unadjusted**  **Adjusted model with mGA**[a](#t4-fn1){ref-type="fn"}   **Adjusted model with oncologists classification**[a](#t4-fn1){ref-type="fn"}                                                                               
  -------------------------------------------- ---------------- -------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------ ------------- ------------------------------ -------------
  **Systematic mGA**                                                                                                                                                                                                                                                                 
  mGA-non-frail                                      148                                                                                                                                                                                                                              
  mGA-frail                                          140        1.86 (1.36; 2.56)                                        **\<0.001**                                                                     1.61 (1.14; 2.27)              **0.007**                                     
  **Oncologists' assessment**                                                                                                                                                                                                                                                        
  Onc-non-frail                                      182                                                                                                                                                                                                                              
  Onc-frail                                          104        1.94 (1.41; 2.66)                                        **\<0.001**                                                                                                                  1.43 (0.97; 2.10)              0.071
  Age (continuous)                                              1.02 (0.99; 1.05)                                        0.185                                                                           1.05 (1.01; 1.09)              **0.010**     1.06 (1.02; 1.10)              **0.002**
  **Gender**                                                                                                                                                                                                                                                                         
  Male                                               162        1[b](#t4-fn2){ref-type="fn"}                                                                                                             1[b](#t4-fn2){ref-type="fn"}                 1[b](#t4-fn2){ref-type="fn"}    
  Female                                             126        0,64 (0.46; 0.89)                                        **0.007**                                                                       0.62 (0.41; 0.93)              **0.019**     0.66 (0.45; 0.98)              **0.040**
  **Cancer type**                                                                                                                                                                                                                                                                    
  Breast                                              30        1[b](#t4-fn2){ref-type="fn"}                                                                                                             1[b](#t4-fn2){ref-type="fn"}                 1[b](#t4-fn2){ref-type="fn"}    
  Prostate                                            56        7.18 (2.20; 23.42)                                       **0.001**                                                                                                      n.s.                                         n.s.
  Other gastrointestinal                              34        19.31 (5.84; 63.79)                                      **\<0.001**                                                                     6.25 (1.75; 22.32)             **0.005**     7.59 (2.12; 27.20)             **0.002**
  Lung                                                59        16.28 (5.05; 52.43)                                      **\<0.001**                                                                     5.17 (1.48; 18.13)             **0.010**     5.85 (1.67; 20.51)             **0.006**
  Colorectal                                          83        4.37 (1.34; 14.26)                                       **0.014**                                                                                                      n.s.                                         n.s.
  Other                                               26        8.40 (2.43; 29.05)                                       **0.001**                                                                                                      n.s.                                         n.s.
  **Stage**                                                                                                                                                                                                                                                                          
  Local                                               73        1[b](#t4-fn2){ref-type="fn"}                                                                                                             1[b](#t4-fn2){ref-type="fn"}                 1[b](#t4-fn2){ref-type="fn"}    
  Locally advanced                                    55        3.04 (1.69; 5.47)                                        **\<0.001**                                                                                                    n.s.                                         n.s.
  Metastasised                                       160        4.63 (2.77; 7.74)                                        **\<0.001**                                                                     1.84 (0.95; 3.58)              0.071         1.77 (0.91; 3.43)              0.094
  **Treatment**                                                                                                                                                                                                                                                                      
  Curative                                            91        1[b](#t4-fn2){ref-type="fn"}                                                                                                             1[b](#t4-fn2){ref-type="fn"}                 1[b](#t4-fn2){ref-type="fn"}    
  Palliative chemotherapy                            126        7.76 (4.67; 12.89)                                       **\<0.001**                                                                     2.54 (1.27; 5.11)              **0.009**     2.57 (1.28; 5.18)              **0.008**
  Other palliative systemic cancer treatment          51        2.74 (1.49; 5.05)                                        **0.001**                                                                                                      n.s                                          n.s.
  Non-systemic palliative treatment                   20        9.47 (4.81; 18.67)                                       **\<0.001**                                                                     4.95 (2.31; 10.63)             **\<0.001**   6.01 (2.79; 12.97)             **\<0.001**
  **ECOG**                                                                                                                                                                                                                                                                           
  0--1                                               244        1[b](#t4-fn2){ref-type="fn"}                                                                                                             1[b](#t4-fn2){ref-type="fn"}                 1[b](#t4-fn2){ref-type="fn"}    
  2--4                                                43        1.79 (1.20; 2.66)                                        **0.004**                                                                                                      n.s.                                         n.s.

Cox regression analysis adjusted for age, sex, diagnosis, stage, treatment and ECOG-PS.

Reference category.

Bold numbers are statistically significant.
